Metformin enhances response to chemotherapy combined with immunotherapy in a triple negative breast cancer in vivo model - PubMed
5 hours ago
- #Metformin
- #Triple-negative breast cancer
- #Chemo-immunotherapy
- Metformin (MTF) enhances the efficacy of chemotherapy (doxorubicin, DOXO) combined with immunotherapy (atezolizumab, ATZ) in a triple-negative breast cancer (TNBC) model.
- In vitro studies determined IC50 values for MTF and DOXO in EMT6 breast cancer cells.
- In vivo studies used BALB/c mice with EMT6 tumors; MTF was administered via drinking water.
- MTF combined with low-dose DOXO and ATZ showed tumor-growth inhibition equivalent to a 20-fold higher DOXO dose plus ATZ.
- The triplet therapy (MTF + DOXO + ATZ) reduced tumor volumes without added toxicity, as evidenced by stable body weight in mice.
- Findings support MTF as a beneficial adjunct to chemo-immunotherapy for TNBC.